Corvidia Stock

corvidiatx.comBioTechFounded: 2015Funding to Date: $91.8MM

Corvidia Therapeutics is a developer of precision therapies using the science of genomics in new ways.

Register for Details

For more details on financing and valuation for Corvidia, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Marc de Garidel
Chief Executive Officer & Board Member
Michael Davidson MD
Co-Founder, Board Member & Chief Scientific Officer
Nicholas Coscia
Controller
Ram Aiyar Ph.D
Co-Founder, Executive Vice President & Head of Business Development
Matt Devalaraja Ph.D
Co-Founder, Executive Vice President & Head of Research & Development
GaoZhong Zhu
Vice President & Head of Pharmaceutical Development and Manufacturing
Douglas Kling
Senior Vice President, Clinical Operations
Kurt Herzog
Senior Business Analyst

Board Members

Aaron Kantoff
Apple Tree Partners
Graziano Seghezzi Ph.D
Sofinnova Partners
Karim Helmy Ph.D
Venrock
Marc de Garidel
Michael Davidson MD
Seth Harrison MD
Apple Tree Partners
Sylvie Grégoire Ph.D
Tyrell Rivers Ph.D

Other companies like Corvidia in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM

News

/PRNewswire/ -- Corvidia Therapeutics Inc., a clinical stage company focused on the research, development and commercialization of transformative therapies in...
Corvidia Therapeutics, a Boston, MA-based biotechnology company focused on the development of precision cardiovascular therapies, raised $26m in Series A funding. The round was co-led by Sofinnova Partners and Apple Tree Partners. In conjunction with the financing, Seth Harrison and Adrien Lemoine, Executive Director, Corporate Development for AstraZeneca, will join Graziano Seghezzi, Partner at Sofinnova …